Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

OBJECTIVES: Evidence comparing the economic and patient values of the World Health Organization’s preferred (dolutegravir 50 mg [DTG]-based) and alternative (low-dose [400 mg] efavirenz [EFV400]-based) first-line antiretroviral regimens is limited. We compared patient-reported outcomes (PROs), costs...

Descripción completa

Detalles Bibliográficos
Autores principales: Bousmah, Marwân-al-Qays, Nishimwe, Marie Libérée, Tovar-Sanchez, Tamara, Lantche Wandji, Martial, Mpoudi-Etame, Mireille, Maradan, Gwenaëlle, Omgba Bassega, Pierrette, Varloteaux, Marie, Montoyo, Alice, Kouanfack, Charles, Delaporte, Eric, Boyer, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882571/
https://www.ncbi.nlm.nih.gov/pubmed/33355914
http://dx.doi.org/10.1007/s40273-020-00987-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882571/
https://www.ncbi.nlm.nih.gov/pubmed/33355914
http://dx.doi.org/10.1007/s40273-020-00987-3

Ejemplares similares